Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: A retrospective cohort study

Sexually Transmitted Diseases

Volumn 41, Issue 2, 2014, Pages 79-85

  Khosropour, Christine M ^a,c   Dombrowski, Julia C ^a,b   Barbee, Lindley A ^a,b   Manhart, Lisa E ^a   Golden, Matthew R ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; DOXYCYCLINE;

ADULT; ARTICLE; CHLAMYDIASIS; COHORT ANALYSIS; DRUG EFFICACY; FOLLOW UP; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIDDLE AGED; PHYSICAL EXAMINATION; RECTAL CHLAMYDIASIS; RECTUM DISEASE; RECURRENCE RISK; RECURRENT INFECTION; REINFECTION; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; TREATMENT DURATION;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DOXYCYCLINE; DRUG ADMINISTRATION SCHEDULE; HOMOSEXUALITY, MALE; HUMANS; MALE; RECTAL DISEASES; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; WASHINGTON;

EID: 84893015376     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000088     Document Type: Article

References (31)

1. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2011. Atlanta, GA: US Department of Health and Human Services, 2012.
2. 2011 King County Sexually Transmitted Diseases Epidemiology Report. 2012. Available at: www.kingcounty.gov/healthservices/health/communicable/std/ statistics.aspx. Accessed October 18, 2013.
3. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 2005; 41:67-74.
4. Cook RL, St George K, Silvestre AJ, et al. Prevalence of chlamydia and gonorrhoea among a population of men who have sex with men. Sex Transm Infect 2002; 78:190-193.
5. Lister NA, Smith A, Tabrizi S, et al. Screening for Neisseria gonorrhoeae and Chlamydia trachomatis in men who have sex with men at male-only saunas. Sex Transm Dis 2003; 30:886-889.
6. Craib KJ, Meddings DR, Strathdee SA, et al. Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men. Genit Med 1995; 71:150-154.
7. Bernstein KT, Marcus JL, Nieri G, et al. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV se-roconversion. J Acquir Immune Defic Syndr 2010; 53:537-543.
8. Zetola NM, Bernstein KT, Wong E, et al. Exploring the relationship between sexually transmitted diseases and HIV acquisition by using different study designs. J Acquir Immune Defic Syndr 2009; 50:546-551.
9. Pathela P, Braunstein SL, Blank S, et al. HIV incidence among men with and those without sexually transmitted rectal infections: Estimates from matching against an HIV case registry. Clin Infect Dis 2013; 57:1203-1209.
10. Chesson HW, Bernstein KT, Gift TL, et al. The cost-effectiveness of screening men who have sex with men for rectal chlamydial and gonococcal infection to prevent hiv infection. Sex Transm Dis 2013; 40:366-371.
11. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1-110.
12. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: A meta-analysis of randomized clinical trials. Sex Transm Dis 2002; 29:497-502.
13. Hathorn E, Opie C, Goold P. What is the appropriate treatment for the management of rectal Chlamydia trachomatis in men and women? Sex Transm Infect 2012; 88:352-354.
14. Stamm WE, Tam M, Koester M, et al. Detection of Chlamydia trachomatis inclusions in Mccoy cell cultures with fluorescein-conjugated monoclonal antibodies. J Clin Microbiol 1983; 17: 666-668.
15. Apewokin SK, Geisler WM, Bachmann LH. Spontaneous resolution of extragenital chlamydial and gonococcal infections prior to therapy. Sex Transm Dis 2010; 37:343-344.
16. Workowski KA, Lampe MF, Wong KG, et al. Long-term eradication of Chlamydia trachomatis genital infection after antimicrobial therapy. Evidence against persistent infection. JAMA 1993; 270: 2071-2075.
17. Gaydos CA, Crotchfelt KA, Howell MR, et al. Molecular amplification assays to detect chlamydial infections in urine specimens from high school female students and to monitor the persistence of chlamydial DNA after therapy. J Infect Dis 1998; 177:417-424.
18. Bachmann LH, Desmond RA, Stephens J, et al. Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhea. J Clin Microbiol 2002; 40:3596-3601.
19. Manhart LE, Gillespie CW, Lowens MS, et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: A randomized controlled trial. Clin Infect Dis 2013; 56: 934-942.
20. Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: Emphasizing emerging pathogensVA randomized clinical trial. Clin Infect Dis 2011; 52:163-170.
21. de Vries HJ, Smelov V, Middelburg JG, et al. Delayed microbial cure of lymphogranuloma venereum proctitis with doxycycline treatment. Clin Infect Dis 2009; 48:e53-e56.
22. Elgalib A, Alexander S, Tong CY, et al. Seven days of doxycycline is an effective treatment for asymptomatic rectal Chlamydia trachomatis infection. Int J STD AIDS 2011; 22:474-477.
23. Steedman NM, McMillan A. Treatment of asymptomatic rectal Chlamydia trachomatis: Is single-dose azithromycin effective? Int J STD AIDS 2009; 20:16-18.
24. Drummond F, Ryder N, Wand H, et al. Is azithromycin adequate treatment for asymptomatic rectal chlamydia? Int J STD AIDS 2011; 22:478-480.
25. Girard AE, Girard D, English AR, et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62, 993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 1987; 31:1948-1954.
26. Lode H, Borner K, Koeppe P, et al. Azithromycin-review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother 1996; 37(suppl C):1-8.
27. Amsden GW. Advanced-generation macrolides: Tissue-directed antibiotics. Int J Antimicrob Agents 2001; 18(suppl 1):S11-S15.
28. Twin J, Moore EE, Garland SM, et al. Chlamydia trachomatis genotypes among men who have sex with men in Australia. Sex Transm Dis 2011; 38:279-285.
29. Horner PJ. Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: Duration of therapy may be the key to improving efficacy. Sex Transm Infect 2012; 88:154-156.
30. Suchland RJ, Geisler WM, Stamm WE. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother 2003; 47:636-642.
31. Wang SA, Papp JR, Stamm WE, et al. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: A meeting report. J Infect Dis 2005; 191:917-923.